Topoisomerase inhibitor and platinum-based chemotherapy
This page covers all Topoisomerase inhibitor and platinum-based chemotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Topoisomerase I and DNA.
Targets
Phase 3 pipeline (1)
- combination of irinotecan and cisplatin · Japan Clinical Oncology Group · Oncology
Irinotecan inhibits topoisomerase I, while cisplatin induces DNA crosslinks, both mechanisms leading to cell death in rapidly dividing cancer cells.
Patent intelligence
- topoisomerase inhibitor and platinum based chemotherapy patent landscape — aggregated cliff calendar, attackable patents, originator estates